Articles related to TARGETED THERAPIES

The TROPiCs-04 trial results challenge the current treatment landscape for metastatic urothelial carcinoma, highlighting the need for new strategies post-relapse and the importance of next-generation sequencing in patient selection.

Pirtobrutinib offers a new line of therapy for CLL and SLL patients who have progressed after covalent BTK inhibitors and venetoclax, with a significant overall response rate and manageable adverse events.

In a recent phase 3 trial, asciminib has shown superior efficacy and safety in newly diagnosed chronic myeloid leukemia patients, achieving a higher major molecular response rate at week 48 compared to traditional tyrosine kinase inhibitors.

Interim results from J&J’s Phase I study of JNJ-6420 highlight both promising efficacy in prostate cancer treatment and serious safety concerns, with 60% of patients experiencing severe adverse events.

Menin inhibitors, targeting the menin-KMT2A interaction, have demonstrated significant response rates in treating specific genotypes of AML and ALL, offering a new avenue for personalized leukemia therapy.

Enhertu, now FDA approved for HER2-positive solid tumors, shows a notable objective response rate across pivotal trials, providing a significant new option for patients with advanced disease stages.